Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy

BackgroundCurcumin, a yellow polyphenol extracted from the rhizome of turmeric (Curcuma longa), has potent anti-cancer properties as demonstrated in a plethora of human cancer cell line and animal carcinogenesis models. Nevertheless, widespread clinical application of this relatively efficacious agent in cancer and other diseases has been limited due to poor aqueous solubility, and consequently, minimal systemic bioavailability. Nanoparticle-based drug delivery approaches have the potential for rendering hydrophobic agents like curcumin dispersible in aqueous media, thus circumventing the pitfalls of poor solubility.ResultsWe have synthesized polymeric nanoparticle encapsulated formulation of curcumin – nanocurcumin – utilizing the micellar aggregates of cross-linked and random copolymers of N-isopropylacrylamide (NIPAAM), with N-vinyl-2-pyrrolidone (VP) and poly(ethyleneglycol)monoacrylate (PEG-A). Physico-chemical characterization of the polymeric nanoparticles by dynamic laser light scattering and transmission electron microscopy confirms a narrow size distribution in the 50 nm range. Nanocurcumin, unlike free curcumin, is readily dispersed in aqueous media. Nanocurcumin demonstrates comparable in vitro therapeutic efficacy to free curcumin against a panel of human pancreatic cancer cell lines, as assessed by cell viability and clonogenicity assays in soft agar. Further, nanocurcumin's mechanisms of action on pancreatic cancer cells mirror that of free curcumin, including induction of cellular apoptosis, blockade of nuclear factor kappa B (NFκB) activation, and downregulation of steady state levels of multiple pro-inflammatory cytokines (IL-6, IL-8, and TNFα).ConclusionNanocurcumin provides an opportunity to expand the clinical repertoire of this efficacious agent by enabling ready aqueous dispersion. Future studies utilizing nanocurcumin are warranted in pre-clinical in vivo models of cancer and other diseases that might benefit from the effects of curcumin.

[1]  Shishir Shishodia,et al.  Molecular targets of dietary agents for prevention and therapy of cancer. , 2006, Biochemical pharmacology.

[2]  Sanjeev Banerjee,et al.  Curcumin Suppresses the Paclitaxel-Induced Nuclear Factor-κB Pathway in Breast Cancer Cells and Inhibits Lung Metastasis of Human Breast Cancer in Nude Mice , 2005, Clinical Cancer Research.

[3]  K. Du,et al.  Curcumin, a Major Constituent of Turmeric, Corrects Cystic Fibrosis Defects , 2004, Science.

[4]  Jen-kun Lin,et al.  Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. , 2000, Carcinogenesis.

[5]  S. Srivastava,et al.  Mechanism of inhibition of benzo[a]pyrene-induced forestomach cancer in mice by dietary curcumin. , 1998, Carcinogenesis.

[6]  B. Aggarwal,et al.  Curcumin: Getting Back to the Roots , 2005, Annals of the New York Academy of Sciences.

[7]  S. Pal,et al.  Curcumin Selectively Induces Apoptosis in Deregulated Cyclin D1-expressed Cells at G2 Phase of Cell Cycle in a p53-dependent Manner* , 2005, Journal of Biological Chemistry.

[8]  A. Dennison,et al.  Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration , 2004, British Journal of Cancer.

[9]  B. Aggarwal,et al.  Curcumin (Diferuloylmethane) Inhibits Constitutive and IL-6-Inducible STAT3 Phosphorylation in Human Multiple Myeloma Cells 1 , 2003, The Journal of Immunology.

[10]  Zhiwei Wang,et al.  Retracted: Notch‐1 down‐regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells , 2006, Cancer.

[11]  M. Diederich,et al.  Chemopreventive and therapeutic effects of curcumin. , 2005, Cancer letters.

[12]  V. Torchilin,et al.  Micellar Nanocarriers: Pharmaceutical Perspectives , 2006, Pharmaceutical Research.

[13]  T. Osawa,et al.  Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with gamma-rays. , 1999, Carcinogenesis.

[14]  W. Gradishar,et al.  Albumin-bound paclitaxel: a next-generation taxane , 2006, Expert opinion on pharmacotherapy.

[15]  Marie-Hélène Dufresne,et al.  Block copolymer micelles: preparation, characterization and application in drug delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[16]  S. Jee,et al.  Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. , 2001, Anticancer research.

[17]  S. Dulchavsky,et al.  Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-KB through suppression of IKBA phosphorylation , 2004 .

[18]  Mechanism of inhibition of benzo[a]pyrene-induced forestomach cancer in mice by dietary curcumin. , 1998 .

[19]  R. Sinha,et al.  Cancer risk and diet in India. , 2003, Journal of postgraduate medicine.

[20]  V. Steele,et al.  Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. , 1999, Cancer research.

[21]  N. Ferrara,et al.  Vascular endothelial growth factor and the regulation of angiogenesis. , 2000, Recent progress in hormone research.

[22]  So-Young Park,et al.  Discovery of natural products from Curcuma longa that protect cells from beta-amyloid insult: a drug discovery effort against Alzheimer's disease. , 2002, Journal of natural products.

[23]  Mansoor M Amiji,et al.  Multi-functional polymeric nanoparticles for tumour-targeted drug delivery , 2006, Expert opinion on drug delivery.

[24]  N. Arber,et al.  Celecoxib and Curcumin Synergistically Inhibit the Growth of Colorectal Cancer Cells , 2005, Clinical Cancer Research.

[25]  K. Mohandas,et al.  Epidemiology of digestive tract cancers in India. VI. Projected burden in the new millennium and the need for primary prevention. , 2000, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[26]  G. Cole,et al.  The Curry Spice Curcumin Reduces Oxidative Damage and Amyloid Pathology in an Alzheimer Transgenic Mouse , 2001, The Journal of Neuroscience.

[27]  J. Eshleman,et al.  Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers , 2005, Molecular Cancer Therapeutics.

[28]  B. Aggarwal,et al.  Nuclear factor‐κB and IκB kinase are constitutively active in human pancreatic cells, and their down‐regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis , 2004, Cancer.

[29]  B. Aggarwal,et al.  Curcumin (Diferuloylmethane) Down-Regulates Expression of Cell Proliferation and Antiapoptotic and Metastatic Gene Products through Suppression of IκBα Kinase and Akt Activation , 2006, Molecular Pharmacology.

[30]  M. Ogawa,et al.  Curcumin inhibits interleukin 8 production and enhances interleukin 8 receptor expression on the cell surface , 2002, Cancer.

[31]  Jen-kun Lin,et al.  Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. , 1996, Nutrition and cancer.

[32]  M. Drumm,et al.  Some like it hot: curcumin and CFTR. , 2004, Trends in molecular medicine.

[33]  Kenjiro Ono,et al.  Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro , 2004, Journal of neuroscience research.

[34]  Chi Han,et al.  Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. , 2002, Carcinogenesis.

[35]  A. Khar,et al.  Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2. , 2004, Molecular cancer therapeutics.

[36]  A. Figer,et al.  Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. , 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[37]  Fusheng Yang,et al.  Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.

[38]  A. Kong,et al.  Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. , 2006, Cancer research.

[39]  A. Khar,et al.  Biological effects of curcumin and its role in cancer chemoprevention and therapy. , 2006, Anti-cancer agents in medicinal chemistry.

[40]  S. Dulchavsky,et al.  Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. , 2004, Molecular cancer therapeutics.

[41]  Daniel Normolle,et al.  Dose escalation of a curcuminoid formulation , 2006, BMC complementary and alternative medicine.

[42]  B. Aggarwal,et al.  Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. , 2005, Biochemical pharmacology.

[43]  M. Pirmohamed,et al.  Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. , 2001, Clinical Cancer Research.

[44]  W. You,et al.  Differential sensitivity of human mammary epithelial and breast carcinoma cell lines to curcumin , 1999, Breast Cancer Research and Treatment.

[45]  R. Hruban,et al.  Molecular genetics of pancreatic intraepithelial neoplasia. , 2007, Journal of hepato-biliary-pancreatic surgery.

[46]  A. Singh,et al.  Multiple biological activities of curcumin: a short review. , 2006, Life sciences.

[47]  M. Pirmohamed,et al.  Phase I Clinical Trial of Oral Curcumin , 2004, Clinical Cancer Research.

[48]  B. Aggarwal,et al.  Anticancer potential of curcumin: preclinical and clinical studies. , 2003, Anticancer research.

[49]  S. Wexner,et al.  Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[50]  Rakesh K. Sharma,et al.  Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels , 2006, Journal of drug targeting.

[51]  V. Torchilin,et al.  Targeted polymeric micelles for delivery of poorly soluble drugs , 2004, Cellular and Molecular Life Sciences CMLS.

[52]  Q. Tong,et al.  Apoptosis-inducing effects of curcumin derivatives in human bladder cancer cells , 2006, Anti-cancer drugs.

[53]  Razelle Kurzrock,et al.  Liposome‐encapsulated curcumin , 2005, Cancer.

[54]  G. Kwon,et al.  Polymeric micelles for delivery of poorly water-soluble compounds. , 2003, Critical reviews in therapeutic drug carrier systems.

[55]  K. Mohandas,et al.  Epidemiology of digestive tract cancers in India. V. Large and small bowel. , 1999, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[56]  B. Aggarwal,et al.  Suppression of the Nuclear Factor‐κB Activation Pathway by Spice‐Derived Phytochemicals: Reasoning for Seasoning , 2004, Annals of the New York Academy of Sciences.

[57]  A. Maitra,et al.  Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis , 2005, Journal of drug targeting.

[58]  A. Edelman,et al.  Rescue of ΔF508-CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) by Curcumin: Involvement of the Keratin 18 Network , 2006, Journal of Pharmacology and Experimental Therapeutics.

[59]  Jayanth Panyam,et al.  Biodegradable nanoparticles for drug and gene delivery to cells and tissue. , 2003, Advanced drug delivery reviews.